S1316 – The Malignant Bowel Obstruction Study Forms and Procedures Katie Arnold, MS SWOG Statistical Center Seattle, WA 10/24/2014S1316 Training1.

Slides:



Advertisements
Similar presentations
Cancer Registry Follow-up How we do it
Advertisements

Phase 3: Intervention Site Training
Research and Development Department A Quick Guide to Using EDGE v2 for Researchers Version 1.2 – 23 February
National Cancer Institute Cancer Therapy Evaluation Program (CTEP) presents: How to Obtain Protected Health Information (PHI) from an Outside Healthcare.
Coding for Medical Necessity
Launch Event – 6 th November 2014 Trial Information and Design Isabel Rubie – Trial Manager The NAtional Trial of Tonsillectomy IN Adults: a clinical and.
S MBO Professional Slide Set, Version 01
ATLAS Steering Committee: 24 September 2005 Steering Committee meeting, 24 th September 2005 University of Oxford Examination Schools.
Consenting Withdrawn Subjects for Follow-Up Information Anita Camic Team Leader Research Compliance Administration Tara Bateman Research Compliance Coordinator.
SDSU/UCSD Joint IRB Review Process Wendy Bracken Human Research Protection Program Coordinator /Educator Division of Research Affairs Graduate & Research.
S1316 Data Submission Roxanne Topacio, CCRP SWOG Data Operations Center Seattle, WA October 24, 2014.
Telehealth & Medicare Hospice Conditions of Participation Deborah Randall JD, Attorney/Telehealth Consultant,
Behavioral Health Services for Injured or Ill workers – Collaborative Care Analysis and Recommendations January 22, 2015.
Infection Control and Communicable Diseases By: Darryl Jamison Macon County EMS Training Coordinator.
Trial Procedures and Forms
Assessing the Client - Part 2 [Site Name] Health Home Staff Training Service Model Developed Primary Care Development Corp.
ASCO Presentation Summary: Chemotherapy Treatment Plan and Summary Templates as a Component of Comprehensive Cancer Care Kansas Cancer Partnership University.
Healthcare Personnel Influenza Vaccination Report Training Webinar
1 Efficacy Results NDA (MTP-PE) Laura Lu Statistical Reviewer Office of Biostatistics FDA/CDER.
Improving the quality of medical and surgical care 1 Subarachnoid Haemorrhage.
British Association of Dermatologists’ Biologic Intervention Register (BADBIR) Update November 2007.
TRANSITIONAL CARE NURSING JASON MARCHI, RN, BSN CAROLYN FENN, MS, LSW April 23, 2012 Maristhill Nursing & Rehabilitation Center.
Caveats We are interpreting the guidelines along with you We may have some limited additional insight due to participation during the course of planning.
Mobile Phone Technology and Male Circumcision Programs Scaling-up male circumcision programmes in the Eastern and Southern Africa Region Arusha, Tanzania,
Role of the Oncology Research Team Carmen B. Jacobs, BS, RN,OCN, CCRP U.T.M.D. Anderson Cancer Center Houston, Texas U.S.A.
The basics of Marrow Things to know.... Reasons to hold a marrow drive: ›Patient Focused ›Potential for large minority turnout ›Saturn National Donor.
Project RED The Re-Engineered Discharge JCR’s AHRQ-funded Project Florida Hospital Association June 4, 2010 Deborah M. Nadzam, PhD, FAAN Project Director.
SMART Study Closeout Washington ICC Meeting 03 June 2007.
Good Research, Bad Choices? Mary Coombs. What Makes Something Research Rather Than Treatment?
SARC: Participation and Protocol / Concept Review Robert Maki, MD PhD Memorial Sloan-Kettering Cancer Center.
FGM – THE ENHANCED DATASET DR EMMA TUKMACHI LEAD GP FOR SAFEGUARDING CHILDREN IN TOWER HAMLETS.
Instructor: Mary “Stela” Gallegos, ABD, (RT), (R), (M) Seminar 4.
Smallpox Vaccine Safety and Reporting Adverse Events Department of Health and Human Services Centers for Disease Control and Prevention December 2002.
Quality Education for a Healthier Scotland Overview of Appraisal Processes on SOAR for Appraisers (Primary and Secondary Care)
How To Design a Clinical Trial
**INSERT YOUR TITLE HERE**
Mette Krag, MD, coordinating investigator
Ambulatory Surgical Centers Data Submission: An Overview Mandi Proue, MPH Project Specialist, MN Community Measurement.
Fully accredited since 2006 Tom Conquergood, CIP Working with Quorum October 13, 2015 Thomas Jefferson University.
CESAR patients from trial entry to discharge Data collection and management – the roles of the Data Co-ordinating Centre (DCC) and hospital staff Steven.
HUMAN TESTING: Ethical or unethical?. What is human testing? ■Human subjects research: any research or clinical investigation that involves human subjects.
Serious Adverse Event Reporting Start-up Meeting March 25, 2010 Kingston, ON.
Garnet Anderson Katie Arnold SWOG Statistical Center Fred Hutchinson Cancer Research Center October 24, 2014.
1 Pulminiq™ Cyclosporine Inhalation Solution Pulmonary Drug Advisory Committee Meeting June 6, 2005 Statistical Evaluation Statistical Evaluation Jyoti.
Methodological Issues in Implantable Medical Device(IMDs) Studies Abdallah ABOUIHIA Senior Statistician, Medtronic.
THE SUPPORTIVE SERVICES DEMONSTRATION FOR ELDERLY HOUSEHOLDS IN HUD-ASSISTED MULTIFAMILY HOUSING.
Disclaimer This presentation is intended only for use by Tulane University faculty, staff, and students. No copy or use of this presentation should occur.
Participating in NCTN Studies NCI codes, Rosters, and Roles
Analytical Observational Studies
PRCSG Training Webinar: Budget for Industry Sponsored Studies
Study Design, Study Participation Retrieve Protocol for Executation
S1400 Revisions #4/5 Training Slides
How To Design a Clinical Trial
MAINTAINING THE INVESTIGATOR’S SITE FILE
Clinicaltrials.gov Update
Protocol References Section Title 6.2 Entry Visit 5.1
ADAPTABLE The Aspirin Study
Protocol References Section Title 6.2 Entry Visit 5.1
S1316 – The Malignant Bowel Obstruction Study A Prospective Comparative Effectiveness Trial for Malignant Bowel Obstruction SWOG Study Chairs: Robert S.
A guide to sign-up as a Notetaker with the MU Disability Center.
S1316 – The Malignant Bowel Obstruction Study A Prospective Comparative Effectiveness Trial for Malignant Bowel Obstruction SWOG Study Chairs: Robert S.
S1316 – The Malignant Bowel Obstruction Study Forms and Procedures
S1316 analysis details Garnet Anderson Katie Arnold
Patient/Alternate Contact Person(s) Information Instructions
Snapshot of the Clinical Trials Enterprise as revealed by ClinicalTrials.gov Content downloaded: September 2012.
Volunteer Notetakers How-To Volunteer.
Cashless Process Planned Hospitalization Emergency Hospitalization
NH CARE ACT DECISION TREE
Module 6: Case Report Form (Chart Abstraction)
Preventing Venous Thromboembolism Participating Hospital Survey
Presentation transcript:

S1316 – The Malignant Bowel Obstruction Study Forms and Procedures Katie Arnold, MS SWOG Statistical Center Seattle, WA 10/24/2014S1316 Training1

S1316 Presentation Outline Study timeline Study flow Eligibility and equipoise Randomization (or not) Endpoint and hospitalizations Documenting MBO Treatment Active vs. passive follow-up 10/24/2014S1316 Training2

S1316 General Study Timeline Patient hospitalized with MBO Registration and randomization Patient discharged from hospital Weeks 1 – 13: Weekly calls from site Weeks 17 – 53: Calls every 4 weeks from site Study participation complete 10/24/2014S1316 Training3

Patient Hospitalized with MBO Eligibility Equipoise Informed consent Patient chooses treatment assignment –Randomization (surgery vs. not) –Surgery –No surgery 10/24/2014S1316 Training4

S1316 Registration and Randomization Register Randomize (if patient selected randomization) Complete patient contact form for site Complete and patient contact form for dietary recalls Obtain baseline documentations Administer baseline PRO forms 10/24/2014S1316 Training5

S1316 Patient Discharged from Hospital Collect MBO treatment data Collect hospitalization documentation Submit forms 10/24/2014S1316 Training6

S1316 Weeks Call patient weekly Obtain vital status Administer PRO forms Determine if patient spent any days in the hospital If patient was hospitalized, obtain hospitalization and MBO treatment data Submit forms Dietary recalls every 4 weeks 10/24/2014S1316 Training7

S Week 13 Report endpoint data –Determine which days patient was in the hospital during first 91 days after registration –Use discharge summaries and information from the weekly calls as source docs –Submit S1316 Hospitalization Days Document 10/24/2014S1316 Training8

S Weeks Call patient every 4 weeks Obtain vital status Administer PRO forms Determine if patient spent any days in the hospital Submit forms Dietary recalls every 4 weeks 10/24/2014S1316 Training9

S1316 Study Participation Complete Submit S1316 Off Protocol Notice Participation is complete when a patient: –Completes 53 weeks of follow-up –Dies Patient no longer wishes to receive phone calls but is willing to allow passive follow-up 10/24/2014S1316 Training10

S1316 Eligibility and Equipoise Clinicians must have equipoise for a patient to be eligible. That means the patient’s MBO can reasonably be treated via surgery or non- surgical medical management. Surgery Non-surgical management 10/24/2014S1316 Training11

S1316 Randomization (or not) Meets all eligibility requirements (N=180) Consents to randomization (N=50) Consents to non- randomized treatment (N=130) Surgery (50%) (Arm 1) Non-surgical management (50%) (Arm 2) Surgery (Arm 3) Non-surgical management (Arm 4) 10/24/2014S1316 Training12

S1316 Endpoint and Hospitalizations S1316 Protocol Section 1.1 Primary Objective To compare quality of life, as assessed by the number of days alive and outside of the hospital within the first 91 days (13 weeks) after registration, among patients with malignant bowel obstruction (MBO) who receive surgical intervention and similar patients treated non-surgically. 10/24/2014S1316 Training13

S1316 Obtaining Complete Endpoint Data Need hospitalization status for each day Leverage the weekly calls to cover any missed periods Protocol Section 7.5b 10/24/2014S1316 Training14

Documenting MBO Treatment 3 paper forms to document MBO treatments –S1316 MBO Treatment Form –S1316 MBO Treatment Complications Form –S1316 Somatostatin Analogue Treatment Form S1316 MBO Treatment Form –Surgery –Non-surgical –Home care 10/24/2014S1316 Training15

S1316 Active vs. Passive Follow- Up Active follow-up –Patient allows phone calls and all study activities Passive follow-up –Patient allows all study activities except phone calls –Submit S1316 Protocol Notice ASAP to stop dietary recall contacts No follow-up –Patient does not want any further follow-up of any kind –Request SWOG Consent Withdrawal Form from Data Coordinator 10/24/2014S1316 Training16

S1316 Forms and Documents Overview Form or Document Name Primary Purpose When collected How collected When submitted 10/24/2014S1316 Training17